Inclusion Criteria:

1. Has laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain
reaction (PCR) or other commercial or public health assay in any specimen, as
documented by either of the following:

- PCR positive in sample collected < 72 hours prior to randomization;

- PCR positive in sample collected ≥ 72 hours prior to randomization, with
inability to obtain a repeat sample (e.g. due to lack of testing supplies, or
limited testing capacity, or results taking >24 hours, etc.) or progressive
disease suggestive of ongoing SARS-CoV-2 infection;

2. At least 1 of the following symptoms: Fever, cough, sore throat, malaise, headache,
muscle pain, dyspnea at rest or with exertion, confusion, or respiratory distress;

3. At least 1 of the following signs at Screening or noted in the 24 hours before
Screening:

- PaO2/FiO2 ≤200 when receiving supplemental oxygen. The PaO2/FiO2 may be estimated
from pulse oximetry (Appendix 1) or determined by arterial blood gas;

- If SpO2 ≥97%, must be receiving 10L or more of supplemental oxygen;

4. The presence of a respiratory infiltrate or abnormality consistent with pneumonia that
is documented by either a chest X-ray or computerized tomography scan of the lungs;

5. The patient is ≥ 18 years of age;

6. A female patient of childbearing potential must not attempt to become pregnant for 39
months, and if sexually active with a male partner, is willing to practice acceptable
methods of birth control for 39 months after the last dose of CM4620-IE;

7. A male patient who is sexually active with a female partner of childbearing potential
is willing to practice acceptable methods of birth control for 39 months after the
last dose of CM4620-IE. A male patient must not donate sperm for 39 months;

8. The patient is willing and able to, or has a legal authorized representative (LAR) who
is willing and able to, provide informed consent to participate, and to cooperate with
all aspects of the protocol.

Exclusion Criteria:

1. Expected survival or time to withdrawal of life-sustaining treatments expected to be
<7 days.

2. Do Not Intubate order;

3. Home mechanical ventilation (noninvasive ventilation or via tracheotomy) except for
continuous positive airway pressure or bi-level positive airway pressure (CPAP/BIPAP)
used solely for sleep-disordered breathing;

4. PaO2/FiO2 ≤75 at the time of Screening. The PaO2/FiO2 may be estimated from pulse
oximetry (Appendix 1) or determined by arterial blood gas;

5. Noninvasive positive pressure ventilation;

6. Invasive mechanical ventilation via endotracheal intubation or tracheostomy;

7. Extracorporeal membrane oxygenation (ECMO);

8. Shock defined by the use of vasopressors;

9. Multiple organ dysfunction or failure;

10. Positive Influenza A or B testing if tested as local standard of care;

11. The patient has a history of:

1. Organ or hematologic transplant;

2. HIV;

3. Active hepatitis B, or hepatitis C infection;

12. Current treatment with:

1. Chemotherapy;

2. Immunosuppressive medications or immunotherapy (Section 5.3 for list of
prohibited immunosuppressive medications and immunotherapy) at the time of
consent;

3. Hemodialysis or Peritoneal Dialysis;

13. Have a history of venous thromboembolism (VTE) (deep vein thrombosis [DVT] or
pulmonary embolism [PE]) within 12 weeks prior to screening or have a history of
recurrent (> 1) VTE;

14. The patient is known to be pregnant or is nursing;

15. Currently participating in another study of an investigational drug or therapeutic
medical device at the time of consent;

16. Allergy to eggs or any of the excipients in study drug.